Brain Structure and Clinical Endpoints in Myotonic Dystrophy Type 2

Key facts

Sponsor

Wake Forest University Health Sciences

Principal Investigator

Araya Puwanant, MD, MS

Wake Forest University Health Sciences

Intervention

Non-interventional study(other)

Enrollment

100 enrolled

Eligibility

30-65 years · All sexes

Timeline

2023 – 2027

Study locations (1)

• Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States

Collaborators

National Institute of Neurological Disorders and Stroke (NINDS)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Proximal myotonic myopathy

Additional recruiting or active studies for the same condition.

• ENROLLING BY INVITATIONPHASE3NCT06549400
  An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2 Who Have Completed MEX-DM-302 Study.
  Lupin Ltd.
• RECRUITINGPHASE1, PHASE2NCT06844214
  A Study to Investigate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Gene Therapy in Participants Aged 10 to 50 Years of Age With Non-congenital Myotonic Dystrophy Type 1
  Sanofi
• RECRUITINGNANCT06716931
  Investigating Exercise in Myotonic Dystrophy Type 2 (DM2)
  Massachusetts General Hospital
• RECRUITINGPHASE3NCT06523400
  The Efficacy and Safety of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2
  Lupin Ltd.
• RECRUITINGNCT04003363
  The United Kingdom National Registry for Myotonic Dystrophy
  Newcastle University
• RECRUITINGNCT02398786
  Myotonic Dystrophy Family Registry
  Myotonic Dystrophy Foundation
• RECRUITINGNCT00082108
  Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry
  University of Rochester

See all trials for Proximal myotonic myopathy →